greeksoup/ stock research
Stock research / United States / MRK · Pharmaceutical Preparations · NYSE

Merck & Co., Inc. (MRK)

Merck is a health care company selling prescription medicines, including biologic therapies, vaccines and animal health products. It is managed principally by product and has two operating segments, both reportable: Pharmaceutical, which holds the human medicines and vaccines, and Animal Health. At the end of 2025 it had approximately 75,000 employees worldwide, approximately 30,000 of them in the United States including Puerto Rico, plus approximately 15,000 third-party contractors counted as full-time equivalents. Approximately 21% of employees are covered by collective bargaining agreements, and the voluntary turnover rate for 2025 was approximately 4.8%.

Merck & Co., Inc.

Merck is a health care company selling prescription medicines, including biologic therapies, vaccines and animal health products. It is managed principally by product and has two operating segments, both reportable: Pharmaceutical, which holds the human medicines and vaccines, and Animal Health. At the end of 2025 it had approximately 75,000 employees worldwide, approximately 30,000 of them in the United States including Puerto Rico, plus approximately 15,000 third-party contractors counted as full-time equivalents. Approximately 21% of employees are covered by collective bargaining agreements, and the voluntary turnover rate for 2025 was approximately 4.8%.

Who it sells to differs by product. Human pharmaceutical products go primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organisations and pharmacy benefit managers. Vaccines go primarily to physicians, wholesalers, distributors and government entities. Animal health products go to veterinarians, distributors, animal producers, farmers and pet owners.

Oncology

Keytruda, pembrolizumab, is an anti-PD-1 therapy available for intravenous administration. It is approved as a single agent across a long list of cancers including cervical, classical Hodgkin lymphoma, cutaneous squamous cell, esophageal, head and neck, hepatocellular, melanoma, Merkel cell, microsatellite instability-high or mismatch repair deficient solid tumours, non-small cell lung, primary mediastinal large B-cell lymphoma, tumour mutational burden-high solid tumours and urothelial cancer; as adjuvant treatment after surgery in melanoma, renal cell and lung cancer; in perioperative settings around surgery in lung, triple-negative breast, head and neck and muscle invasive bladder cancer; and in combination with chemotherapy or with other agents such as Lenvima, axitinib, trastuzumab and enfortumab vedotin across further indications. Keytruda Qlex is a subcutaneous fixed combination of pembrolizumab with berahyaluronidase alfa, which enables the subcutaneous route, approved in the United States for the solid tumour indications Keytruda carries and marketed as Keytruda SC in some markets. Welireg treats certain von Hippel-Lindau disease-associated tumours, advanced renal cell carcinoma after prior therapy, and certain pheochromocytoma or paraganglioma. The company also recognises alliance revenue on Lynparza, an oral PARP inhibitor, on Lenvima, an oral receptor tyrosine kinase inhibitor, and on Reblozyl for certain anemias.

Vaccines

Gardasil and Gardasil 9 against human papillomavirus; ProQuad, M-M-R II and Varivax for measles, mumps, rubella and chickenpox; Vaxneuvance, Capvaxive and Pneumovax 23 against pneumococcal disease; RotaTeq against rotavirus gastroenteritis in infants; and Enflonsia, a long-acting monoclonal antibody preventing respiratory syncytial virus lower respiratory tract disease in newborns and infants entering their first RSV season.

The rest of the pharmaceutical segment

Hospital acute care holds Bridion, which reverses two types of neuromuscular blocking agent used in surgery, Prevymis against cytomegalovirus infection in transplant recipients, the antibacterial Zerbaxa and Dificid for C. difficile-associated diarrhoea. Cardiometabolic and respiratory holds Winrevair and Adempas for pulmonary arterial hypertension, Verquvo for chronic heart failure with reduced ejection fraction, and Ohtuvayre, an inhaled PDE3/4 inhibitor for chronic obstructive pulmonary disease. Virology holds Lagevrio for COVID-19, available in the United States under Emergency Use Authorization, and the HIV treatments Isentress, Delstrigo and Pifeltro. Neuroscience holds Belsomra for insomnia, and diabetes holds Januvia and Janumet.

Animal Health

Veterinary pharmaceuticals, vaccines, health management services and digitally connected identification, traceability and monitoring products. On the livestock side the range runs across cattle, swine, poultry and farmed fish: the Nuflor antibiotic range, the Bovilis and Vista vaccine lines, Banamine and Resflor for bovine respiratory disease and inflammation, Safe-Guard de-wormer, the Porcilis and Circumvent swine vaccine lines, the Nobilis and Innovax poultry vaccines, Exzolt against mite infestations, Slice and Imvixa for sea lice in salmon, Aquaflor for farmed fish, and Allflex Livestock Intelligence for animal identification, monitoring and traceability. On the companion animal side, Bravecto is a line of oral, topical and injectable parasite control products for dogs and cats, running from the original twelve-week product to a one-month dog product, a one-year injectable and a two-month cat product; alongside it sit the Sentinel oral parasitic range, the Nobivac dog and cat vaccine lines, Numelvi for pruritus associated with allergic dermatitis, Caninsulin and Vetsulin for diabetes mellitus in dogs and cats, and Sure Petcare identification products including the Home Again microchip and pet recovery system.

Who it competes with

Other worldwide research-based pharmaceutical companies, smaller research companies with a narrower therapeutic focus, generic drug manufacturers and animal health companies. The filing points to generic and biosimilar competition as its own products mature, to competitors' technological advances, industry consolidation and patents, and to the rising frequency with which patent rights are challenged.

From Merck's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Merck became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 4 November 2026
Revenue
$18.1 billion
+4.7% on the year · +8.9% on the quarter
Q4 FY2024Q3 FY2026
Net income
$5.1 billion
-12.4% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$2.04
-12.1% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 24 February 2026
Revenue
$65.0 billion
+1.3% on the year
FY2018FY2025
Net income
$18.3 billion
+6.6% on the year
FY2018FY2025
Diluted EPS
$7.28
+8.0% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsMerck (MRK) reported revenue of $65.0 billion for fiscal 2025, the year ended 31 December 2025, up 1.3% on the year before. Net income was $18.3 billion and diluted earnings per share $7.28. Revenue was $64.2 billion in fiscal 2024, $60.1 billion in fiscal 2023, $59.3 billion in fiscal 2022 and $48.7 billion in fiscal 2021. Net income in the same years was $17.1 billion, $365 million, $14.5 billion and $13.0 billion. Over the twelve months to 30 September 2026, Merck reported revenue of $67.4 billion and net income of $2.5 billion. Revenue grew 9.4% a year, compounded, over the five years to fiscal 2025. Merck declared $3.40 a share in dividends over the last four quarters and had 2.47 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $53.8 billion of debt and $9.6 billion of cash. At the close of 6 November 2026 the market cap of Merck was $361.8 billion, 151.3 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE5.5%
ROCEn/a
Operating marginn/a
Net margin3.6%
FCF margin21.9%
Interest covern/a
Debt to equity1.20x
Cash conversion7.62x
Share count, last 12 months-0.7%
Sales CAGR, 3 years3.1%
Profit CAGR, 3 years7.9%
EPS, TTM$0.97

At the close of 6 November 2026

Price$146.75
Market cap$361.8 billion
Stock P/E151.3x
Price to book8.1x
EV / EBITDAn/a
Dividend yield2.3%
Market cap / sales5.4x
52-week high$156.45
52-week low$85.78
Price, 1 year71.1%
Price CAGR, 3 years12.2%
Price CAGR, 5 years12.5%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt Merck & Co., Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
MRKgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue13,52115,90114,59314,95913,83014,48715,03515,96214,63115,77516,11216,65715,62415,52915,80617,27616,40016,28616,60718,085
Cost of revenue3,8735,3804,2163,9343,8813,9264,0244,2643,9123,5403,7454,0803,8283,4193,5573,8555,5514,1954,3954,892
Gross profit9,64810,52110,37711,0259,94910,56111,01111,69810,71912,23512,36712,57711,79612,11012,24913,42110,84912,09112,21213,193
Gross margin71%66%71%74%72%73%73%73%73%78%77%76%75%78%77%78%66%74%74%73%
R&D3,0672,5762,7984,3993,7754,27613,3213,3079,6273,9923,5005,8624,5843,6214,0484,2343,88612,5929,7414,537
SG&A2,8302,3232,5122,5202,6872,4792,7022,5192,8042,4832,7392,7312,8632,5522,6492,6332,8992,7002,9042,886
Interest expense208243240244235242277317310303310330328313305327412479525546
Pre-tax income3,9094,8614,4873,5833,5133,650-5,3355,620-2,0465,6706,0064,0904,1705,9034,9996,7453,420-3,534-6835,559
Tax rate2%11%12%9%14%23%n/a15%n/a16%9%23%10%14%11%14%13%n/an/a9%
Net income3,7584,3103,9443,2483,0172,821-5,9754,745-1,2264,7625,4553,1573,7435,0794,4275,7852,963-4,240-1,3355,065
Net margin28%27%27%22%22%19%-40%30%-8%30%34%19%24%33%28%33%18%-26%-8%28%
Diluted EPS$1.48$1.70$1.55$1.28$1.18$1.11-$2.35$1.86-$0.48$1.87$2.14$1.24$1.48$2.01$1.76$2.32$1.19-$1.72-$0.54$2.04
Operating cash flown/a4,7614,3025,6024,4301,3393,7047,7172463,0905,6379,2913,4502,5003,2937,8222,8573,9185,3706,558
Capital expenditure1,2089841,1291,1261,1491,0079659029898617917839371,3287649871,0339918931,040
Free cash flown/a3,7773,1734,4763,2813322,7396,815-7432,2294,8468,5082,5131,1722,5296,8351,8242,9274,4775,518
Buybacks18.00.00.00.00.01493384663931222514444891,1641,3451,3231,252874757653
Dividends paid1,6431,7451,7701,7471,7501,8531,8851,8551,8521,9501,9861,9531,9512,0502,0772,0312,0182,1052,1442,099
Shares outstanding2,528m2,529m2,533m2,535m2,539m2,537m2,538m2,534m2,533m2,533m2,535m2,530m2,526m2,511m2,498m2,482m2,472m2,470m2,467m2,465m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007 †FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021FY2022FY2023FY2024FY2025TTM
Revenue24,19823,85027,42845,98748,04747,26744,03342,23739,49839,80740,12242,29439,12141,51848,70459,28360,11564,16865,01167,378
Cost of revenue6,1415,5829,01918,39616,87116,44616,95416,76814,93414,03012,91213,50912,01613,61813,62617,41116,12615,19316,38219,033
Gross profit18,05718,26818,40927,59131,17630,82127,07925,46924,56425,77727,21028,78527,10527,90035,07841,87243,98948,97548,62948,345
Gross margin74.6%76.6%67.1%60.0%64.9%65.2%61.5%60.3%62.2%64.8%67.8%68.1%69.3%67.2%72.0%70.6%73.2%76.3%74.8%71.8%
Research and development4,8834,8055,84511,1118,4678,1687,5037,1806,70410,26110,3399,7529,72413,39712,24513,54830,53117,93815,78930,756
Selling, general and administrative7,5577,3778,54313,12513,73312,77611,91111,60610,31310,01710,07410,1029,4558,9559,63410,04210,50410,81610,73311,389
Interest expensen/a2514607156957148017326726937547728938318069621,1461,2711,3571,962
Pre-tax incomen/an/a15,2901,6537,3348,7395,54517,2835,4014,6596,5218,7017,1715,86313,87916,4441,88919,93621,0674,762
Income tax95.31,9992,2686719422,4401,0285,3499427184,1032,5081,5651,3401,5211,9181,5122,8032,8042,312
Effective tax raten/an/a14.8%40.6%12.8%27.9%18.5%30.9%17.4%15.4%62.9%28.8%21.8%22.9%11.0%11.7%80.0%14.1%13.3%48.6%
Net income3,2757,80812,9018616,2726,1684,40411,9204,4423,9202,3946,2209,8437,06713,04914,51936517,11718,2542,453
Net margin13.5%32.7%47.0%1.9%13.1%13.0%10.0%28.2%11.2%9.8%6.0%14.7%25.2%17.0%26.8%24.5%0.6%26.7%28.1%3.6%
Diluted EPS$1.49$3.63$5.65$0.28$2.02$2.00$1.47$4.07$1.56$1.41$0.87$2.32$3.81$2.78$5.14$5.71$0.14$6.74$7.28$0.97
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2016 to FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Pharmaceutical segment35,15135,39037,68934,10036,61042,75452,00553,58357,40058,14290.1%
Animal Health3,4783,8754,2124,3934,7035,5685,5505,6255,8776,3549.9%
Other segments38539725017523n/an/an/an/an/an/a
Not assigned to a part in the filing793n/an/an/an/an/a1,728907n/an/an/a
Pharmaceutical segmentAnimal HealthOther segments FY2016 to FY2020
39.7FY201738.7FY201948.3FY202159.2FY202364.5FY2025

$ billion; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Not assigned to a part in the filing is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Profit by segment FY2016 to FY2025

The profit before tax each segment reports. Costs Merck does not charge to a segment are left out, so the segments can add up to more than the company's own profit before tax.

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Margin
FY2025
Pharmaceutical segment22,14123,01824,87123,44826,10630,97736,85238,88044,53345,75478.7%
Animal Health1,3571,5521,6591,6121,6691,9501,9631,7371,9382,13133.5%
Other segments146275103-71n/an/an/an/an/an/a
Pharmaceutical segmentAnimal HealthOther segments FY2016 to FY2020
24.8FY201725.1FY201932.9FY202140.6FY202347.9FY2025

$ billion; the figure over a bar is all the segments together; a year a segment lost money, it hangs below the line. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Pharmaceutical segment90%96%
Animal Health10%4%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has a profit before tax figure. A margin is a segment's profit before tax over its own sales.

Revenue by region FY2016 to FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States18,47817,42418,34618,42019,58822,42527,20628,48032,27736,51056.2%
Europe, Middle East and Africa10,95311,47812,21310,49611,54713,34114,49313,25414,04114,58022.4%
Latin America2,1552,3392,4152,0151,8902,2062,5823,0863,4593,4105.2%
Asia Pacific (other than Japan and China)2,4832,7512,9092,1262,1132,4073,6143,2253,0582,9834.6%
Other1,4571,4221,0151,2751,0271,2212,5682,1042,5592,8784.4%
Japan2,8463,1223,2122,6092,6022,7263,6293,1643,2802,7114.2%
China1,4351,5862,1842,1802,7514,3785,1916,8025,4941,9393.0%
United StatesEurope, Middle East and AfricaLatin AmericaAsia Pacific (other than Japan and China)OtherJapanChina
40.1FY201739.1FY201948.7FY202160.1FY202365.0FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Merck's adjusted EPS landed at or above the top of the range in 7, inside it in 1 and under it in 1 of the 9 years shown (FY2011 to FY2020).

+0.3%FY2011−0.8%FY2012−5.7%FY2013+3.5%FY2015+0.8%FY2016+2.8%FY2017+2.6%FY2018+10.0%FY2019+2.9%FY2020
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2011$3.64 to $3.76$3.77
FY2012$3.75 to $3.85$3.82
FY2013$3.60 to $3.70$3.49
FY2015$3.32 to $3.47$3.59
FY2016$3.60 to $3.75$3.78
FY2017$3.72 to $3.87$3.98
FY2018$4.08 to $4.23$4.34
FY2019$4.57 to $4.72$5.19
FY2020$5.62 to $5.77$5.94
FY2026 forecast
Adjusted EPS $5.00 to $5.15, given 3 February 2026. Its result comes with the fourth-quarter results for FY2026.
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007 †FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow6,9996,5723,39210,82212,38310,02211,6547,98912,53810,3766,44710,92213,44010,25314,10919,09513,00621,46816,47218,703
Capital expenditure1,0111,2981,4611,6781,7231,9541,5481,3171,2831,6141,8882,6153,3694,4294,4484,3883,8633,3724,1123,957
Free cash flow5,9885,2731,9319,14410,6608,06810,1066,67211,2558,7624,5598,30710,0715,8249,66114,7079,14318,09612,36014,746
Free cash flow margin24.7%22.1%7.0%19.9%22.2%17.1%23.0%15.8%28.5%22.0%11.4%19.6%25.7%14.0%19.8%24.8%15.2%28.2%19.0%21.9%
Cash from investing-2,810-1,8343,156-3,497-2,890-6,805-3,148-374-4,758-3,2102,6794,314-2,629-9,443n/a-4,960-14,083-7,734-13,741-28,332
Cash from financing-4,866-5,522-1,638-5,441-6,904-3,267-5,990-15,242-5,387-9,044-10,006-13,160-8,861-2,832n/a-9,119-4,810-7,032-1,9221,100
Depreciation and amortisation1,9881,6312,5767,3817,4276,9786,9886,6916,3755,4714,6764,5193,6523,4693,1783,9243,8284,5045,845n/a
Share-based compensation3303484165093693352762782993003123483884414795416457618201,057
Buybacks1,4302,7250.01,5931,9212,5916,5167,7034,1863,4344,0149,0914,7801,2818400.01,3461,3065,0843,536
Dividends paid3,3073,2783,2154,7344,6915,1165,1575,1705,1175,1245,1675,1725,6956,2156,6107,0127,4457,8408,1768,366
Dividend per share$1.52$1.52$1.52$1.52$1.56$1.69$1.73$1.77$1.81$1.85$1.89$1.99$2.26$2.48$2.64$2.80$2.96$3.12$3.28n/a
Diluted shares, weightedn/a2,143m2,273m3,120m3,094m3,076m2,996m2,928m2,841m2,787m2,748m2,679m2,580m2,541m2,538m2,542m2,547m2,541m2,507m2,478m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a2,465m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007 †FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019 †FY2020 †FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity20,59118,75859,05854,37654,51753,02049,76548,64744,67640,08834,33626,70125,90725,31738,18445,99137,58146,31352,60644,893
Non-controlling interestn/a2,4092,4272,4292,4262,4432,56114491.022023318194.087.073.067.054.059.056.053.0
Debtn/a3,94317,50017,88217,51520,56925,06021,40326,41224,84224,35325,10026,30031,80033,10030,70035,10037,10049,30053,800
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a7681,3351,2251,013928877901n/a
Other liabilitiesn/a22,08533,32931,09430,67030,10028,25928,14130,60030,22728,95030,65531,32833,04933,11231,38933,01232,75734,00334,027
Total liabilities and equityn/a47,196112,314105,781105,128106,132105,64598,335101,77995,37787,87282,63784,39791,588105,694109,160106,675117,106136,866132,773
Owned
Fixed assetsn/a12,00018,27417,08216,29716,03014,97313,13612,50712,02612,43913,29114,29717,00019,27921,42223,05123,77925,31625,904
Goodwilln/a1,43912,03812,37812,15512,13412,30112,99217,72318,16218,28418,25318,06918,88221,26421,20421,19721,66821,57921,951
Intangible assetsn/a52547,75739,45634,30229,08323,80120,38622,60217,30514,18313,10414,19614,10122,93320,26918,01116,37026,68124,476
Investmentsn/a7,6097253,4764,8999,99511,63521,79317,94219,24214,5317,1322,2437853701,5135049109561,703
Cash and equivalents5,3364,3689,31110,90013,53113,45115,6217,4418,5246,5156,0927,9659,6768,0628,09612,6946,84113,24214,5659,550
Receivablesn/a2,8166,6037,3448,2617,6727,1846,6266,4847,0186,8737,0716,7786,8039,2309,45010,34910,27811,77512,744
Inventoryn/a2,0918,0555,8686,2546,5356,2265,5714,7004,8665,0965,4405,9785,5545,9535,9116,3586,1096,6586,164
Other assetsn/a16,3479,5509,2779,42911,23213,90410,39011,29710,24310,37410,38113,16020,40118,56916,69720,36424,75029,33630,281
Total assetsn/a47,196112,314105,781105,128106,132105,64598,335101,77995,37787,87282,63784,39791,588105,694109,160106,675117,106136,866132,773
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded5.1%9.4%3.1%4.9%
Profit growth, compounded15.2%20.9%7.9%-87.1%
Return on equity, average24.4%27.7%24.2%34.7%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Merck's revenue in fiscal 2025?

Merck (MRK) reported revenue of $65.0 billion for fiscal 2025, the year ended 31 December 2025, up 1.3% on the year before.

How much did Merck earn in fiscal 2025?

Net income was $18.3 billion for fiscal 2025, and diluted earnings per share $7.28.

What is Merck's P/E ratio?

At the close of 6 November 2026, Merck traded at 151.3 times its earnings over the twelve months to 30 September 2026.

What is Merck's market cap?

The market cap of Merck was $361.8 billion at the close of 6 November 2026.

Does Merck pay a dividend?

Yes. Merck declared $3.40 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on MRK

Dividends$3.40 a share over the four quarters to 30 September 2026, a 2.32% yield
Filings20 in twelve months: 8 current reports (8-K), about 4 results of operations; 2 other events; 1 officer or director change; 1 shareholder vote
Planned insider sales22 Form 144 notices in twelve months, $74.4 million; latest 2 November 2026
Options tapeput/call 0.84 by open interest at the 6 November 2026 close; the straddle prices a 3.6% move to 13 November 2026
13F holders3,863 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading34 sales and 0 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest26.8 million shares short, 2.97 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20264 November 2026EDGAR
10-Q30 June 20267 August 2026EDGAR
10-Q31 March 20264 May 2026EDGAR
10-K31 December 202524 February 2026EDGAR
10-Q30 September 20255 November 2025EDGAR
10-Q30 June 20255 August 2025EDGAR
10-Q31 March 20252 May 2025EDGAR
10-K31 December 202425 February 2025EDGAR
10-Q30 September 20246 November 2024EDGAR
10-Q30 June 20245 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.